Bioxytran’s Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
Rhea-AI Summary
Bioxytran (OTCQB: BIXT) has announced significant progress in developing ProLectin-M, its broad-spectrum antiviral drug. The company has completed dosing in its dose optimization clinical trial, marking a crucial milestone in the drug's development.
ProLectin-M targets galectin fold on viral spike proteins and has shown impressive clinical results: 100% response rate (negative PCR tests) by day 7 and 88% response rate by day 3 in double-blinded placebo-controlled trials. The drug has demonstrated effectiveness against SARS-CoV-2, influenza, and RSV, with no viral rebounds during the 14-day observation period.
The drug's development, supported by an active FDA IND application, utilizes proprietary linear complex carbohydrate structures designed with nuclear magnetic resonance and AI to neutralize viral infectiousness.
Positive
- Completed dose optimization clinical trial with promising results
- 100% response rate by day 7 and 88% by day 3 in clinical trials
- Broad-spectrum effectiveness against multiple respiratory viruses
- Active IND application with FDA
- No viral rebounds observed during 14-day observation period
Negative
- Still in clinical development phase, not yet FDA approved
- Trading on OTCQB market rather than major exchange
News Market Reaction 1 Alert
On the day this news was published, BIXT declined 2.44%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA
BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is pleased to announce significant progress in development of its broad-spectrum antiviral drug, ProLectin-M. The company has successfully completed dosing of its dose optimization clinical trial, bringing it one step closer to introducing a groundbreaking oral antiviral that could redefine the treatment landscape for respiratory infections, potentially reducing the need for traditional vaccinations.
ProLectin-M, Bioxytran’s leading drug candidate, targets the galectin fold on the spike proteins of viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus (RSV). Peer-reviewed published studies have demonstrated its ability to neutralize these viruses with high efficacy, achieving a complete response (negative PCR tests) in all subjects by day 7 and an
“This is a pivotal moment for Bioxytran and the field of virology,” said Dr. David Platt, CEO of Bioxytran. “Our broad-spectrum antiviral platform exploits conserved target regions present on the spike proteins that allows our linear complex carbohydrate molecules designed with the aid of nuclear magnetic resonance and artificial intelligence to neutralize the virus’s infectiousness. We have the potential to neutralize a wide range of respiratory viruses, including those that mutate rapidly. ProLectin-M will fundamentally change how we combat respiratory infections. The timing of this advancement aligns with a significant shift in U.S. health policy.”
“We believe the redirection of resources away from mRNA vaccines creates a unique opportunity for Bioxytran,” said Dr. Leslie Ajayi, Bioxytran’s Chief Medical Officer. “Our data suggests ProLectin-M could become a first-line therapy for respiratory patients with no underlying medical conditions.
Bioxytran’s platform, rooted in the emerging field of Glycovirology, leverages proprietary linear complex carbohydrate chemical structures to block galectins, proteins that facilitate viral attachment to host cells. In vitro studies have shown ProLectin-M’s potential to neutralize not only SARS-CoV-2 but also influenza and RSV, with ongoing research exploring its efficacy against other viruses like Epstein-Barr Virus (EBV).
About Bioxytran, Inc.
Bioxytran, Inc. is at the forefront of developing linear complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for stroke treatment. When utilized an FDA approved device to detect tissue oxygenationat the time of diagnosis BXT-25 has the possibility of reducing what is known as the time until needle by over
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What are the clinical trial results for Bioxytran's ProLectin-M antiviral drug?
Which viruses can Bioxytran's ProLectin-M target?
How does Bioxytran's ProLectin-M antiviral drug work?
What is the current development status of BIXT's ProLectin-M?
Who is leading Bioxytran's ProLectin-M development?
